A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada

Study Identifier
CMO-EPI-WH-0626
CT.gov Identifier
NCT04567095
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Other
Sign up for trial alerts

Study Details

Medical Condition
  • Uterine Fibroids
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patients who have received Fibristal within 6 months of completing the survey. * Patients who have provided permission to share their responses in aggregate with Health Canada. * Patients who have provided informed consent for their participation in the survey.
    Exclusion Criteria:
    * Patients who participated in the cognitive pre-testing of the survey questionnaire to be used for the study. * Patients who have been direct employees of Allergan, ICON, Health Canada, or Professional Targeted Marketing (PTM) within the past year.

    Protocol Summary

    This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Patients in Canada.

    Study Locations

    Location
    Status
    Location
    Clinical Trials Registry Team
    Irvine, California, United States, 92622
    Status
    Not applicable